BREAKING: Covaxin Approved For Phase II-III Trials In 2-18 Years Age Group

BREAKING: Covaxin Approved For Phase II-III Trials In 2-18 Years Age Group

India.com

New Delhi: COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years, Niti Aayog’s Dr. VK Paul said on Tuesday. While addressing a press conference, Dr. VK Paul further added that the trials will begin in the next 10-12 days. “COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days,” Dr. Paul said.

On ‘anti-COVID drug 2DG’ developed by DRDO, Dr Paul said, "We will examine the drug in COVID-19 National Task Force for adding it to the treatment protocol.


Read all the latest updates on COVID-19 here.
Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

177404865

Cases

160265862

Recovered

3839186

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019